I should also mention if there's uncertainty about the term but provide the most plausible interpretation based on available information. It's important to note that without more context, the article is speculative but grounded in common practices within the industry. Including examples of how pharmaceutical companies adopt in-person strategies and the benefits they offer could add value. Additionally, touching on digital transformation and how in-person efforts complement it might provide a balanced view.